首页> 美国卫生研究院文献>Chemical Science >An ultrasensitive polydopamine bi-functionalized SERS immunoassay for exosome-based diagnosis and classification of pancreatic cancer
【2h】

An ultrasensitive polydopamine bi-functionalized SERS immunoassay for exosome-based diagnosis and classification of pancreatic cancer

机译:一种基于外泌体的胰腺癌诊断和分类的超灵敏多巴胺双功能SERS免疫测定

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Early diagnosis and metastasis monitoring for pancreatic cancer are extremely difficult due to a lack of sensitive liquid biopsy methods and reliable biomarkers. Herein, we developed easy-to-prepare and effective polydopamine-modified immunocapture substrates and an ultrathin polydopamine-encapsulated antibody-reporter-Ag(shell)–Au(core) multilayer (PEARL) Surface-Enhanced Raman Scattering (SERS) nano-tag with a quantitative signal of the Raman reporter at 1072 cm–1, which achieved ultrasensitive and specific detection of pancreatic cancer-derived exosomes with a detection limit of only one exosome in 2 μL of sample solution (approximately 9 × 10–19 mol L–1). Furthermore, by analyzing a 2 μL clinical serum sample, the migration inhibitory factor (MIF) antibody-based SERS immunoassay could not only discriminate pancreatic cancer patients (n = 71) from healthy individuals (n = 32), but also distinguish metastasized tumors from metastasis-free tumors, and Tumor Node Metastasis (TNM) P1–2 stages from the P3 stage (the discriminatory sensitivity was 95.7%). Thus, this novel immunoassay provides a powerful tool for the early diagnosis, classification and metastasis monitoring of pancreatic cancer patients.
机译:由于缺乏灵敏的液体活检方法和可靠的生物标记物,胰腺癌的早期诊断和转移监测极为困难。在这里,我们开发了易于制备和有效的聚多巴胺修饰的免疫捕获底物,以及超薄的聚多巴胺包裹的抗体-报告物-Ag(壳)-Au(核心)多层(PEARL)表面增强拉曼散射(SERS)纳米标签在1072 cm –1 处有拉曼报告基因的定量信号,实现了胰腺癌衍生的外泌体的超灵敏和特异性检测,在2μL样品溶液中检出限仅为一个外泌体(约9 ×10 –19 mol L –1 )。此外,通过分析2μL临床血清样品,基于迁移抑制因子(MIF)抗体的SERS免疫分析不仅可以区分胰腺癌患者(n = 71)与健康个体(n = 32),而且还可以将转移性肿瘤与无转移的肿瘤,以及从P3期到P1-2期的肿瘤淋巴结转移(TNM)(区分敏感性为95.7%)。因此,这种新颖的免疫测定为胰腺癌患者的早期诊断,分类和转移监测提供了强大的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号